TELA · TELA Bio, Inc. · Webcasts, Transcripts & Audio
$0.82
-0.04 (-4.64%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Nov 10, 2026
Market Cap
$37.06M
Shares
45.19M
Volume · Nov 13
129.18K
Avg daily vol (3M)
224.59K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
TELA Bio, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for TELA Bio, Inc. (TELA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-10
TELA Bio, Inc. (TELA) Q3 2026 Earnings Call Transcript
Confident tone
Abdominal wound management
Ovatex clinical application
Patient recovery outcomes
Revenue
$18.96M
▼ 8.4% YoY Diluted EPS
$-0.16
Gross margin
64.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-10
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call
Revenue
$19.29M
▼ 4.5% YoY Diluted EPS
$-0.20
Gross margin
72.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
Confident tone
Ovatex LTR product launch
Second half 2026 outlook and guidance skew
Board of directors refresh
Revenue
$19.06M
▲ 2.9% YoY Diluted EPS
$-0.21
Gross margin
65.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
Positive tone
Product Portfolio and Innovation
Commercial Organization Rebuild
Sales Rep Hiring and Productivity
Revenue
$20.87M*
▲ 18.2% YoY Gross margin
65.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
TELA Bio, Inc. (TELA) Q3 2025 Earnings Call Transcript
Positive tone
Revenue growth and commercial milestones
Sales force build-out and productivity
Geographic expansion and market access
Revenue
$20.69M
▲ 9.1% YoY Diluted EPS
$-0.19
Gross margin
67.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript
Confident tone
Revenue milestone and growth
Portfolio transition from niche to broad hernia provider
New leadership and execution
Revenue
$20.20M
▲ 25.5% YoY Diluted EPS
$-0.22
Gross margin
69.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
TELA Bio, Inc. (TELA) Q1 2025 Earnings Call Transcript
Positive tone
Revenue growth and guidance
Tariff exposure and gross margin
Commercial organization expansion
Revenue
$18.52M
▲ 11.5% YoY Diluted EPS
$-0.25
Gross margin
67.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
TELA Bio, Inc. (TELA) Q4 2024 Earnings Call Transcript
Cautious tone
Sales force turnover and realignment
Product portfolio and market opportunity (OviTex)
Commercial strategy: TM/AS team structure
Revenue
$17.65M*
▲ 3.8% YoY Gross margin
63.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript
Confident tone
Quarterly revenue growth and product momentum
2025 outlook and guidance
International/European expansion
Revenue
$18.96M
▲ 25.9% YoY Diluted EPS
$-0.42
Gross margin
67.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
TELA Bio, Inc. (TELA) Q2 2024 Earnings Call Transcript
Positive tone
Q2 revenue growth and headwinds
OviTex and LIQUIFIX product portfolio
Path to profitability and OpEx discipline
Revenue
$16.09M
▲ 11% YoY Diluted EPS
$-0.51
Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
TELA Bio, Inc. (TELA) Q1 2024 Earnings Call Transcript
Confident tone
GPO and IDN Contracts
LIQUIFIX Product Suite
OviTex PRS / Plastic and Reconstructive Surgery
Revenue
$16.60M
▲ 39.4% YoY Diluted EPS
$-0.23
Gross margin
68.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
Confident tone
Product Portfolio Expansion (LIQUIFIX and OviTex IHR)
GPO Contracts and Hospital Adoption
Operating Losses and Cash Burn
Revenue
$17.00M*
▲ 46.3% YoY Gross margin
68.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
TELA Bio, Inc. (TELA) Q3 2023 Earnings Call Transcript
Revenue
$15.05M
▲ 34.9% YoY Diluted EPS
$-0.45
Gross margin
69.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
TELA Bio, Inc. (TELA) Q2 2023 Earnings Call Transcript
Revenue
$14.49M
▲ 39.3% YoY Diluted EPS
$-0.46
Gross margin
70.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-18
TELA Bio, Inc. (TELA) Q1 2023 Earnings Call Transcript
Revenue
$11.91M
▲ 44.7% YoY Diluted EPS
$-0.63
Gross margin
66.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-21
TELA Bio, Inc. (TELA) Q4 2022 Earnings Call Transcript
Revenue
$11.62M*
▲ 38.8% YoY Gross margin
70.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
TELA Bio, Inc. (TELA) Q3 2022 Earnings Call Transcript
Revenue
$11.16M
▲ 45.8% YoY Diluted EPS
$-0.64
Gross margin
65.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
TELA Bio, Inc. (TELA) Q2 2022 Earnings Call Transcript
Revenue
$10.41M
▲ 37.7% YoY Diluted EPS
$-0.88
Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
TELA Bio, Inc. (TELA) Q1 2022 Earnings Call Transcript
Revenue
$8.23M
▲ 40.1% YoY Diluted EPS
$-0.75
Gross margin
60.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-21
TELA Bio, Inc. (TELA) Q4 2021 Earnings Call Transcript
Revenue
$8.37M*
▲ 47.8% YoY Gross margin
67.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
TELA Bio, Inc. (TELA) Q3 2021 Earnings Call Transcript
Revenue
$7.65M
▲ 44.1% YoY Diluted EPS
$-0.57
Gross margin
60.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
TELA Bio, Inc. (TELA) Q2 2021 Earnings Call Transcript
Revenue
$7.56M
▲ 115.5% YoY Diluted EPS
$-0.57
Gross margin
67.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
TELA Bio, Inc. (TELA) Q1 2021 Earnings Call Transcript
Revenue
$5.88M
▲ 57.7% YoY Diluted EPS
$-0.56
Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-24
TELA Bio, Inc. (TELA) Q4 2020 Earnings Call Transcript
Revenue
$5.67M*
▲ 16.5% YoY Gross margin
64.6%
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
TELA Bio, Inc. (TELA) Q3 2020 Earnings Call Transcript
Revenue
$5.31M
▲ 33.7% YoY Gross margin
61.9%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-12
TELA Bio, Inc. (TELA) Q2 2020 Earnings Call Transcript
Revenue
$3.51M
▲ 6.2% YoY Gross margin
59.5%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
TELA Bio, Inc. (TELA) Q1 2020 Earnings Call Transcript
Revenue
$3.73M
▲ 12.7% YoY Gross margin
59.0%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-10
TELA Bio, Inc. (TELA) Q4 2019 Earnings Call
Revenue
$4.86M*
Gross margin
60.9%
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 webcasts
Key facts
CIK
1561921
CUSIP
872381108
13F (30d)
42 filings
38 filers
Visit website
Investor relations